Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB000928 With or Without Ruxolitinib in Anemia Due to Myelofibrosis
jRCT2031210445Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of zilurgisertib in myelofibrosis (MF), post-essential thrombocythemia myelofibrosis (PET-MF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (3 arms), sponsored by Incyte. Primary endpoint: Number of treatment-related adverse events. Started May 2022; status: active, not recruiting.
02
Drugs
zilurgisertib
03
Conditions
myelofibrosis (MF)post-essential thrombocythemia myelofibrosis (PET-MF)post-polycythemia vera myelofibrosis (PPV-MF)anaemia
Beyond the preview
Go deeper on jRCT2031210445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210445.